High frequency of EGFR mutations found in Asian population

February 15, 2014

Adenocarcinoma histology, female sex, never-smoking status, and Asian ethnicity have been considered the most important factors associated with EGFR mutations in non-small cell lung cancer and response to EGFR inhibitors. A recent study has found that, within the Asian population, the frequency of EGFR mutations associated with other demographic and clinical characteristics is higher than previously reported, even in patients with a history of smoking, suggesting that mutation testing should be done on a broader basis among Asian patients with advanced adenocarcinoma of the lung.

The PIONEER study is the first prospective, multinational epidemiologic study to document the frequency of EGFR mutations in in the Asian population. The PIONEER authors found that EGFR mutations were present in 51.4% of stage IIIB or IV adenocarcinomas of the lung among 1,450 patients from seven regions of Asia. Previous reports have suggested a frequency of approximately 30% among the Asian population (compared with 20% among the white population). The findings of the PIONEER study are published in the February issue of the International Association for the Study of Lung Cancer's journal, the Journal of Thoracic Oncology (JTO).

The frequency of EGFR mutations was high among women (61.1%) and never-smokers (60.7%), but EGFR mutations were also common among men (44%), occasional smokers (51.6%), and previous smokers (43.2%). With regard to Asian regions, the frequency was highest in Vietnam (64.2%) and lowest in India (22.2%).

"The frequency of EGFR mutations in demographic and clinical subgroups of Asian patients in PIONEER suggests that EGFR should be considered for all patients with stage IIIB or IV adenocarcinoma of the lung in Asian populations," says first author Yuankai Shi, MD, of the Department of Medical Oncology, Cancer Institute/Hospital, Beijing, China. More widespread mutation testing would help to ensure the optimal identification and treatment of with adenocarcinomas that harbor EGFR .

Coauthors of the study include IASLC members Sumitra Thongprasert, MD, of the Department of Internal Medicine, Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand; Chun-Ming Tsai, MD, of the Chest Department, Taipei Veteran's General Hospital, Taipei, Taiwan; Gerardo Cornelio, MD, of the St. Peregrine Oncology Unit, San Juan De Dios Hospital, Pasay City, Philippines; and Pan-Chyr Yang, MD, of the Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan who led the study.

Related Stories

Patients with EGFR exon 20 insertions have poorer prognosis

January 15, 2013

Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non–small-cell lung cancer (NSCLC). Little is known about cancers harboring these mutations aside from their ...

Tumors with ALK rearrangements can harbor more mutations

April 22, 2013

The identification of potentially targetable kinase mutations has been an exciting advancement in lung cancer treatment. Although the mutations driving many lung carcinomas remain unknown, approximately 50 percent of lung ...

Recommended for you

New treatment options for a fatal leukemia

July 27, 2015

In industrialized countries like in Europe, acute lymphoblastic leukemia is the most common form of cancer in children. An international research consortium lead by pediatric oncologists from the Universities of Zurich and ...

Exciting results from cancer immunoagent study

July 20, 2015

(Medical Xpress)—Cancer therapies have improved incrementally over the years, but cancer treatment largely remains analogous to forest fire suppression, in which the spread of fire is contained with deliberate controlled ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.